|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCEстатья
- Автор: Петрова Галина Дмитриевна
- Сборник: EHA 2022
- Серия: HemaSphere | 2022; 6:S3
- Год издания: 2022
- Место издания: HemaSphere Journal Vienna
- Первая страница: 3083
- Последняя страница: 3083
- Номер статьи: PB1756
- Аннотация: The current modern chemotherapy (CHT) protocols for ALL, taking into account prognostic factors, including assessment and monitoring of MRD, in the general group of patients (pts) allow achieving complete remission (CR) in 80–90% cases. In adult pts with primary B-cell ALL CR rates of 80–90% are routinely achieved with standard multidrug chemotherapy, however, 5-year disease free survival is only around 40%. The prognosis of pts with relapses or refractory disease are dismal, 5-y overall survival after treatment failure is about 10%. Therapy of r/r B-ALL remains a challenge. Intensification of CHT has not been successful secondary to high toxicity rates. Each subsequent line of therapy reduces the response rate and the duration of the achieved remission, which complicates the sequential implementation of allogeneic hematopoietic cell transplantation (alloHCT). Novel targeted therapies have been shown to improve outcomes in pts with adult B-ALL. Inotuzumab ozogamicin (InO), a new antibody–drug conjugate, has shown significant activity in adult patients with r/r B-ALL.
- Добавил в систему: Петрова Галина Дмитриевна